Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study.

Mariani P, Blumberg J, Landau A, Lebrun-Jezekova D, Botton E, Beatrix O, Mayeur D, Herve R, Maisonobe P, Chauvenet L.

J Clin Oncol. 2012 Dec 10;30(35):4337-43. doi: 10.1200/JCO.2011.40.5712. Epub 2012 Oct 29.

PMID:
23109694
2.

EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.

Vinik AI, Wolin EM, Liyanage N, Gomez-Panzani E, Fisher GA; ELECT Study Group *.

Endocr Pract. 2016 Sep;22(9):1068-80. doi: 10.4158/EP151172.OR. Epub 2016 May 23.

PMID:
27214300
3.

Somatostatin analogs for malignant bowel obstruction resulting from peritoneal carcinomatosis.

Zelek L, Laval G, Asselain B.

J Clin Oncol. 2013 Jul 1;31(19):2519-20. doi: 10.1200/JCO.2012.48.4634. Epub 2013 Jun 3. No abstract available.

PMID:
23733778
4.

Palliative interventions in patients with peritoneal metastases and malignant bowel obstruction.

Bellavance EC, Alexander HR Jr.

J Clin Oncol. 2012 Dec 10;30(35):4290-1. doi: 10.1200/JCO.2012.45.0536. Epub 2012 Oct 29. No abstract available.

PMID:
23109693
5.

Randomized, placebo-controlled, double-blind study of the efficacy of lanreotide 30 mg PR in the treatment of pancreatic and enterocutaneous fistulae.

Gayral F, Campion JP, Regimbeau JM, Blumberg J, Maisonobe P, Topart P, Wind P; Lanreotide Digestive Fistula.

Ann Surg. 2009 Dec;250(6):872-7.

PMID:
19953707
6.

SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction.

Laval G, Rousselot H, Toussaint-Martel S, Mayer F, Terrebonne E, François E, Brixi H, Nguyen T, Bourdeix I, Bisot-Locard S, Zelek L; SALTO Study Group.

Bull Cancer. 2012 Feb 1;99(2):E1-9. doi: 10.1684/bdc.2011.1535.

7.

Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators.

N Engl J Med. 2014 Jul 17;371(3):224-33. doi: 10.1056/NEJMoa1316158.

8.
9.
10.

Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.

Lucas T, Astorga R; Spanish-Portuguese Multicentre Autogel Study Group on Acromegaly.

Clin Endocrinol (Oxf). 2006 Sep;65(3):320-6.

11.

Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study.

Bajetta E, Procopio G, Catena L, Martinetti A, De Dosso S, Ricci S, Lecchi AS, Boscani PF, Iacobelli S, Carteni G, De Braud F, Loli P, Tartaglia A, Bajetta R, Ferrari L.

Cancer. 2006 Nov 15;107(10):2474-81.

12.

Lanreotide Autogel 90 mg and lymphorrhea prevention after axillary node dissection in breast cancer: a phase III double blind, randomized, placebo-controlled trial.

Gauthier T, Garuchet-Bigot A, Marin B, Mollard J, Loum O, Fermeaux V, Jammet I, Kanoun D, Maubon A, Aubard Y.

Eur J Surg Oncol. 2012 Oct;38(10):902-9. doi: 10.1016/j.ejso.2012.05.009. Epub 2012 Jun 15.

PMID:
22703757
13.
14.

Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.

Capdevila J, Sevilla I, Alonso V, Antón Aparicio L, Jiménez Fonseca P, Grande E, Reina JJ, Manzano JL, Alonso Lájara JD, Barriuso J, Castellano D, Medina J, López C, Segura Á, Carrera S, Crespo G, Fuster J, Munarriz J, García Alfonso P.

BMC Cancer. 2015 Jul 4;15:495. doi: 10.1186/s12885-015-1512-6.

15.

Recommendations for bowel obstruction with peritoneal carcinomatosis.

Laval G, Marcelin-Benazech B, Guirimand F, Chauvenet L, Copel L, Durand A, Francois E, Gabolde M, Mariani P, Rebischung C, Servois V, Terrebonne E, Arvieux C; French Society for Palliative Care; French Society for Digestive Surgery; French Society for Gastroenterology; French Association for Supportive Care in Oncology; French Society for Digestive Cancer.

J Pain Symptom Manage. 2014 Jul;48(1):75-91. doi: 10.1016/j.jpainsymman.2013.08.022. Epub 2014 May 4. Review.

PMID:
24798105
17.

Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, de Man RA, Drenth JP.

Gastroenterology. 2009 Nov;137(5):1661-8.e1-2. doi: 10.1053/j.gastro.2009.07.052. Epub 2009 Jul 29.

PMID:
19646443
18.

Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.

Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Gomez-Panzani E, Ruszniewski P; CLARINET Investigators.

Endocr Relat Cancer. 2016 Mar;23(3):191-9. doi: 10.1530/ERC-15-0490. Epub 2016 Jan 7.

19.

Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.

Shimatsu A, Teramoto A, Hizuka N, Kitai K, Ramis J, Chihara K.

Endocr J. 2013;60(5):651-63. Epub 2013 Jan 19.

20.

[Hepatic encephalopathy after injection of lanreotide, a somatostatin analog].

Robin E, Lebrec D, Hammel P, Bernades P, Ruszniewski P.

Gastroenterol Clin Biol. 1996;20(11):1014-6. French.

PMID:
9119171

Supplemental Content

Support Center